NCT04309539

Brief Summary

This patient population is typically elderly and frail. They are at risk of adverse effects secondary to inadequate pain management such as prolonged admissions and poor functional outcomes. Regional analgesia is preferred due to their opioid-sparing effects and reduction in related adverse effects but The analgesia from these blocks is only moderate and literature suggests that the obturator nerve (ON) is not covered.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
100

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Sep 2020

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 12, 2020

Completed
4 days until next milestone

First Posted

Study publicly available on registry

March 16, 2020

Completed
6 months until next milestone

Study Start

First participant enrolled

September 21, 2020

Completed
8 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2021

Completed
9 months until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2022

Completed
Last Updated

September 23, 2020

Status Verified

September 1, 2020

Enrollment Period

8 months

First QC Date

March 12, 2020

Last Update Submit

September 22, 2020

Conditions

Outcome Measures

Primary Outcomes (1)

  • Time of performance of Spinal Anesthesia

    Is defined as the time measured from the start of positioning to the completion of the intrathecal bupivacaine injection

    just before surgery.

Secondary Outcomes (18)

  • Pain measurement at rest

    immediately and 1 hour at PACU, then in the surgical ward at 2,4,6,8,12,18 and 24 h after surgery.

  • Pain measurement on movement

    immediately and 1 hour at PACU, then in the surgical ward at 2,4,6,8,12,18 and 24 h after surgery.

  • Pain measurement during positioning for spinal anesthesia

    Just before surgery

  • The severity of postoperative pain at rest

    immediately and 1 hour at PACU, then in the surgical ward at 2,4,6,8,12,18 and 24 h after surgery.

  • The severity of postoperative pain on movement

    immediately and 1 hour at PACU, then in the surgical ward at 2,4,6,8,12,18 and 24 h after surgery.

  • +13 more secondary outcomes

Study Arms (2)

Fascia iliaca block

ACTIVE COMPARATOR

Patients will receive Fascia iliaca block

Procedure: Fascia iliaca block

combined LFCN block with PENG block

ACTIVE COMPARATOR

Patients will receive a combined lateral femoral cutaneous nerve block with pericapsular nerve group block

Procedure: combined LFCN block with PENG block

Interventions

A linear probe will be placed in the sagittal plane to the inguinal ligament to obtain an image of "bow-tie sign" formed by the muscle fascias, a spinal needle will be inserted 1 cm cephalad Using an in-plane approach, the fascia iliaca is penetrated, 30 mL of bupivacaine 0.25% before spinal anesthesia.

Fascia iliaca block

With the patient supine, the linear probe is placed parallel to the inguinal ligament. LFCN appear as a hypoechoic oval structure between the tensor fascia lata and Sartorius muscles. The needle is inserted in plane. 5 mL of LA is injected. The PENG block will be performed in the supine position. A curvilinear probe will be placed transversely over the anterior inferior iliac spine and then rotated counterclockwise 45 degrees. the ilio pubic eminence, the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle will be observed. A spinal needle will be inserted in plane to the plane between the psoas tendon and the pubic ramus. 25 mL of bupivacaine 0.25% will be injected

combined LFCN block with PENG block

Eligibility Criteria

Age50 Years - 90 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • American Society of Anesthesiologists (ASA) physical status I, II and III.

You may not qualify if:

  • Patient refusal.
  • Neuromuscular diseases
  • Hematological diseases
  • Bleeding abnormality
  • Coagulation abnormality.
  • Psychiatric diseases.
  • Local skin infection at the site of the block.
  • Local skin sepsis at the site of the block
  • Known intolerance to the study drugs.
  • Body Mass Index \> 40 Kg/m2.
  • Multiple trauma patients.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Mansoura University, emergency hospital

Al Mansurah, DK, 050, Egypt

RECRUITING

MeSH Terms

Conditions

Proximal Femoral Fractures

Condition Hierarchy (Ancestors)

Femoral Neck FracturesHip FracturesFemoral FracturesFractures, BoneWounds and InjuriesHip InjuriesLeg Injuries

Study Officials

  • Mona A Hasheesh, MD

    Professor of Anesthesia and Surgical Intensive care,,P

    STUDY CHAIR
  • Eiad A Ramzy, MD

    Associate Professor of Anesthesia and Surgical Intensive care,

    STUDY DIRECTOR

Central Study Contacts

Eiad A Ramzy, MD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Masking Details
Single-blind study
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 12, 2020

First Posted

March 16, 2020

Study Start

September 21, 2020

Primary Completion

June 1, 2021

Study Completion

March 1, 2022

Last Updated

September 23, 2020

Record last verified: 2020-09

Data Sharing

IPD Sharing
Will share

Yes, Study Protocol Statistical Analysis Plan (SAP) Informed Consent Form (ICF) Clinical Study Report (CSR)

Shared Documents
STUDY PROTOCOL, SAP, ICF, CSR
Time Frame
after completing the study and being accepted for publication.
Access Criteria
The data will be accessible to the investigators and PRS administrators with hiding the identifiers for the patients

Locations